Has Elliot Min, MD received payments from drug or device companies?

Yes. Drug and device makers reported $53,203 in general payments to Elliot Min, MD across 86 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elliot Min, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elliot Min, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elliot Min, MD

Neurological Surgery · Tacoma, WANPI 1134510589

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,516 of the $53,203 with a category attached, or 89.3%. Pacira Pharmaceuticals Incorporated accounts for 89.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $48,055 and has fallen 99.2% since, to $399 in 2025. Among neurological surgery clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,203in general payments, 2019–2025

Across 86 payments — averaging $618.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pacira Pharmaceuticals Incorporated$48K
Medtronic$1K
Synthes GmbH$1K
Stryker$775
Globus Medical$502
Augmedics Inc.$294
plus $2K from 21 others

What the payments were for

Speaking & faculty fees$47,51689%
Travel & lodging$1,2122%
Food & beverage$4,2788%
Education$1960%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pacira Pharmaceuticals Incorporated	6	$47,516
Medtronic(2 entities)	13	$1,137
Synthes GmbH	1	$1,055
Stryker	8	$775
Globus Medical(2 entities)	4	$502
Augmedics Inc.	2	$294
Spineology Inc.	1	$286
Boston Scientific	3	$254
UCB, Inc.	6	$206
Lilly USA, LLC	7	$187
Neurelis, Inc.	6	$113
Eisai Inc.	3	$86
Argenx US, Inc.	3	$85
SK Life Science, Inc.	3	$83
Kls-martin L.p.	1	$82
Alnylam Pharmaceuticals Inc.	3	$75
Alphatec Spine, Inc	1	$69
Lundbeck LLC	2	$68
Teva Pharmaceuticals USA, Inc.	3	$65
AbbVie	2	$61
Acadia Pharmaceuticals Inc	2	$55
CSL Behring	1	$32
Ipsen Biopharmaceuticals, Inc	1	$28
Bioventus LLC	1	$26
Novartis	1	$24
Integra Lifesciences Corporation	1	$20
Zimmer Biomet	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,203 in reported general payments places this provider in the 90th percentile of 175 neurological surgery providers in Washington.

See all neurological surgery providers in Washington →

Medicare billing

Part B allowed, 2024

$117,561

Medicare patients

170

Services billed

344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Methocarbamol	14	$330
Meloxicam	36	$288
Gabapentin	19	$123

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Tacoma

Christine HammerTacoma$5K
Rod OskouianSeattle$2.4M
Christoph HofstetterSeattle$768K
David YamBrush Prairie$471K
Stephen MonteithSeattle$151K
Allan HellerSpokane$132K
Jean-Christophe LevequeSeattle$120K
Vijay YanamadalaSeattle$85K
Hoan Vu TranSeattle$78K
Martin RutkowskiSeattle$62K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →